Onabotulinumtoxin A is under clinical development by AbbVie and currently in Phase III for Unspecified Musculoskeletal Disorders.

Onabotulinumtoxin A is under clinical development by AbbVie and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase II drugs for Chronic Obstructive ...

Dr. Vigna concludes,“Botox will remain the standard of care for treatment of spasticity, equinus deformity of the foot that causes plantar flexion of the foot, and is useful for both hip ...

Meghan Trainor claims "nobody warned me" before she went a little too far with Botox, which left her unable to smile. The 30-year-old pop singer made a cheerful comeback during a recent interview ...

BURLINGTON, Ontario, December 17, 2024--(BUSINESS WIRE)--Merz Therapeutics, a business of Merz Group and a leader in the field of neurotoxins, today announced that Health Canada approved XEOMIN ...

"This approval means that adult patients who have suffered from a stroke and are experiencing lower limb spasticity in the ankle and foot will now have a safe and effective treatment option," explains ...

The most commonly reported use of botulinum toxin among these cases was treatment of limb muscle spasticity associated with cerebral palsy. For Botox, doses ranged from 6.25 to 32 Units/kilogram ...

Merz Therapeutics, a business of Merz Group and a leader in the field of neurotoxins, announced that Health Canada approved Xeomin (incobotulinumtoxinA) for the treatment of post-stroke lower limb ...